Tweenvest Stocks

Nippon Shinyaku Co., Ltd. (TSE: 4516)

Health Care · Pharmaceuticals · JP

¥3,372.00

+0.12% today · -0.4% 1Y

Nippon Shinyaku Co., Ltd. (TSE: 4516) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.44B and employs 2,309 people.

Over the last twelve months the share price has lost 0.4%, trading between 3.19K and 6.53K.

Tweenvest scores Nippon Shinyaku Co., Ltd. across four factors: quality 85/100, value 82/100, growth 39/100, dividend 75/100. Its strongest factor is quality.

4516 price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$1.44B
Revenue (TTM)
$1.11B
P/E
7.20
EPS
468.47
Dividend yield
3.68%
Beta (5Y)
-0.30
52-week high
¥6,529.00
52-week low
¥3,187.00
Avg volume (3M)
—
Shares outstanding
67.40M
Employees
2,309
Next earnings
—

About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.

ISIN
JP3717600005
Founded
1911
Listed since
Jan 1, 2001
Exchange
The Tokyo Stock Exchange
Currency
JPY
CompanyMarket capPriceDay
Marksans Pharma LimitedNSEI: MARKSANS$1.45BRs309.10-5.07%
Ningbo Menovo Pharmaceutical Co., Ltd.SHSE: 603538$1.44BCN¥28.45-0.49%
ST Pharm Co.,Ltd.KOSDAQ: A237690$1.44B₩92,900.00-0.43%
Omeros CorporationNasdaqGM: OMER$1.44B$19.89+0.30%
Xiamen Kingdomway Group CompanySZSE: 002626$1.43BCN¥15.89-1.49%
Zhejiang Jolly Pharmaceutical Co.,LTDSZSE: 300181$1.38BCN¥13.25+0.30%
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.SHSE: 688076$1.37BCN¥29.01+0.28%
Shandong Lukang Pharmaceutical Co.,Ltd.SHSE: 600789$1.29BCN¥8.28+5.48%

Browse every Pharmaceuticals company →

Figures last refreshed Oct 11, 2026.